One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction
This study sought to compare clinical outcomes between bioresorbable scaffolds (BRS) and durable polymer everolimus-eluting metallic stents (DP-EES) in patients with acute myocardial infarction (AMI) undergoing successful percutaneous coronary intervention (PCI). From March 2016 to October 2017, 952...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-07, Vol.15 (7), p.e0235673 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | e0235673 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Kim, Yongcheol Bae, SungA Jeong, Myung Ho Ahn, Youngkeun Kim, Chong Jin Cho, Myeong Chan Baumbach, Andreas Gogas, Bill D King, 3rd, Spencer B |
| description | This study sought to compare clinical outcomes between bioresorbable scaffolds (BRS) and durable polymer everolimus-eluting metallic stents (DP-EES) in patients with acute myocardial infarction (AMI) undergoing successful percutaneous coronary intervention (PCI).
From March 2016 to October 2017, 952 patients with AMI without cardiogenic shock undergoing successful PCI with BRS (n = 136) or DP-EES (n = 816) were enrolled from a multicenter, observational Korea Acute Myocardial Infarction Registry.
In the crude population, there was no significant difference in the 1-year rate of device-oriented composite endpoint (DOCE) and device thrombosis between the BRS and DP-EES groups (2.2% vs. 4.8%, hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.13-1.41, p = 0.163; 0.7% vs. 0.5%, HR 1.49, 95% CI 0.16-13.4, p = 0.719, respectively). BRS implantation was opted in younger patients (53.7 vs. 62.6 years, p < 0.001) with low-risk profiles, and intravascular image-guided PCI was more preferred in the BRS group (60.3% vs. 27.2%, p < 0.001).
At 1-year follow-up, no differences in the rate of DOCE and device thrombosis were observed between patients with AMI treated with BRS and those treated with DP-EES. Our data suggest that imaging-guided BRS implantation in young patients with low risk profiles could be a reasonable strategy in the setting of AMI. |
| doi_str_mv | 10.1371/journal.pone.0235673 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2422008869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A629018361</galeid><doaj_id>oai_doaj_org_article_78bfac29309d4f458c5b7cc95ff3cdb5</doaj_id><sourcerecordid>A629018361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-4edcb9ae0d232a0ce816bac37631bab0b8d8443d04586a1313ae1086cdc827873</originalsourceid><addsrcrecordid>eNptkk2P0zAQhiMEYpeFf4AgEhLikuKPxHEuSKsVHyuttBc4WxNn3Lpy42I7K_rvcdvsqkWcbI2fed-Z8RTFW0oWlLf089pPYQS32PoRF4TxRrT8WXFJO84qwQh_fnK_KF7FuCak4VKIl8UFZ6JuCOsuiz_3I1Y7hFCiMVaD3pUwDmUEg2lXelPiAwbv7GaKFbop2XFZ9tYHjD700DssowZjvBtiaccyrXIA0wHLyaCnhOVm5zWEwYLLiIGgk_Xj6-KFARfxzXxeFb--ff1586O6u_9-e3N9V-mGNqmqcdB9B0gGxhkQjZKKHjRvBafZn_RykHXNB1I3UgDllANSIoUetGStbPlV8f6ou3U-qnloUbGaMUKkFF0mbo_E4GGttsFuIOyUB6sOAR-WCkKy2qFqZW9As46TbqhNttRN32rdNcZwPfRN1voyu039JpeOYwrgzkTPX0a7Ukv_oFpet5TyLPBpFgj-94QxqY2NGp2DEf10qJuTRtSSZvTDP-j_u5upJeQG8vx99tV7UXUtWEeo5GKv9fGEWiG4tIp-_99-jOdgfQR18DEGNE-9UaL2e_lYhNrvpZr3Mqe9O53LU9LjIvK_tBjhyA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2422008869</pqid></control><display><type>article</type><title>One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Kim, Yongcheol ; Bae, SungA ; Jeong, Myung Ho ; Ahn, Youngkeun ; Kim, Chong Jin ; Cho, Myeong Chan ; Baumbach, Andreas ; Gogas, Bill D ; King, 3rd, Spencer B</creator><creatorcontrib>Kim, Yongcheol ; Bae, SungA ; Jeong, Myung Ho ; Ahn, Youngkeun ; Kim, Chong Jin ; Cho, Myeong Chan ; Baumbach, Andreas ; Gogas, Bill D ; King, 3rd, Spencer B ; Other Korea Acute Myocardial Infarction Registry Investigators</creatorcontrib><description>This study sought to compare clinical outcomes between bioresorbable scaffolds (BRS) and durable polymer everolimus-eluting metallic stents (DP-EES) in patients with acute myocardial infarction (AMI) undergoing successful percutaneous coronary intervention (PCI).
From March 2016 to October 2017, 952 patients with AMI without cardiogenic shock undergoing successful PCI with BRS (n = 136) or DP-EES (n = 816) were enrolled from a multicenter, observational Korea Acute Myocardial Infarction Registry.
In the crude population, there was no significant difference in the 1-year rate of device-oriented composite endpoint (DOCE) and device thrombosis between the BRS and DP-EES groups (2.2% vs. 4.8%, hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.13-1.41, p = 0.163; 0.7% vs. 0.5%, HR 1.49, 95% CI 0.16-13.4, p = 0.719, respectively). BRS implantation was opted in younger patients (53.7 vs. 62.6 years, p < 0.001) with low-risk profiles, and intravascular image-guided PCI was more preferred in the BRS group (60.3% vs. 27.2%, p < 0.001).
At 1-year follow-up, no differences in the rate of DOCE and device thrombosis were observed between patients with AMI treated with BRS and those treated with DP-EES. Our data suggest that imaging-guided BRS implantation in young patients with low risk profiles could be a reasonable strategy in the setting of AMI.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0235673</identifier><identifier>PMID: 32645029</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Absorbable Implants - adverse effects ; Acute Disease - therapy ; Adult ; Aged ; Biocompatibility ; Biology and Life Sciences ; Biomedical materials ; Cardiology ; Cardiovascular Agents - therapeutic use ; Care and treatment ; Clinical outcomes ; Confidence intervals ; Consent ; Drug-Eluting Stents - adverse effects ; Endpoint Determination ; Engineering and Technology ; Everolimus - therapeutic use ; Female ; Glycoproteins ; Heart attack ; Heart attacks ; Hospitals ; Humans ; Hypertension ; Implantation ; Implants ; Inhibitor drugs ; Male ; Medicine ; Medicine and Health Sciences ; Middle Aged ; Myocardial infarction ; Myocardial Infarction - surgery ; Myocardial Infarction - therapy ; Patient outcomes ; Patients ; Percutaneous Coronary Intervention - adverse effects ; Physical Sciences ; Polymers ; Proportional Hazards Models ; Republic of Korea ; Risk assessment ; Scaffolds ; Stents ; Studies ; Surgical implants ; Thromboembolism ; Thrombosis ; Thrombosis - etiology ; Tissue Scaffolds - adverse effects ; Treatment Outcome</subject><ispartof>PloS one, 2020-07, Vol.15 (7), p.e0235673</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Kim et al 2020 Kim et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-4edcb9ae0d232a0ce816bac37631bab0b8d8443d04586a1313ae1086cdc827873</citedby><cites>FETCH-LOGICAL-c515t-4edcb9ae0d232a0ce816bac37631bab0b8d8443d04586a1313ae1086cdc827873</cites><orcidid>0000-0003-2424-810X ; 0000-0003-1484-4645 ; 0000-0002-0047-0227</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347113/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347113/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32645029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Yongcheol</creatorcontrib><creatorcontrib>Bae, SungA</creatorcontrib><creatorcontrib>Jeong, Myung Ho</creatorcontrib><creatorcontrib>Ahn, Youngkeun</creatorcontrib><creatorcontrib>Kim, Chong Jin</creatorcontrib><creatorcontrib>Cho, Myeong Chan</creatorcontrib><creatorcontrib>Baumbach, Andreas</creatorcontrib><creatorcontrib>Gogas, Bill D</creatorcontrib><creatorcontrib>King, 3rd, Spencer B</creatorcontrib><creatorcontrib>Other Korea Acute Myocardial Infarction Registry Investigators</creatorcontrib><title>One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>This study sought to compare clinical outcomes between bioresorbable scaffolds (BRS) and durable polymer everolimus-eluting metallic stents (DP-EES) in patients with acute myocardial infarction (AMI) undergoing successful percutaneous coronary intervention (PCI).
From March 2016 to October 2017, 952 patients with AMI without cardiogenic shock undergoing successful PCI with BRS (n = 136) or DP-EES (n = 816) were enrolled from a multicenter, observational Korea Acute Myocardial Infarction Registry.
In the crude population, there was no significant difference in the 1-year rate of device-oriented composite endpoint (DOCE) and device thrombosis between the BRS and DP-EES groups (2.2% vs. 4.8%, hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.13-1.41, p = 0.163; 0.7% vs. 0.5%, HR 1.49, 95% CI 0.16-13.4, p = 0.719, respectively). BRS implantation was opted in younger patients (53.7 vs. 62.6 years, p < 0.001) with low-risk profiles, and intravascular image-guided PCI was more preferred in the BRS group (60.3% vs. 27.2%, p < 0.001).
At 1-year follow-up, no differences in the rate of DOCE and device thrombosis were observed between patients with AMI treated with BRS and those treated with DP-EES. Our data suggest that imaging-guided BRS implantation in young patients with low risk profiles could be a reasonable strategy in the setting of AMI.</description><subject>Absorbable Implants - adverse effects</subject><subject>Acute Disease - therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Biocompatibility</subject><subject>Biology and Life Sciences</subject><subject>Biomedical materials</subject><subject>Cardiology</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Care and treatment</subject><subject>Clinical outcomes</subject><subject>Confidence intervals</subject><subject>Consent</subject><subject>Drug-Eluting Stents - adverse effects</subject><subject>Endpoint Determination</subject><subject>Engineering and Technology</subject><subject>Everolimus - therapeutic use</subject><subject>Female</subject><subject>Glycoproteins</subject><subject>Heart attack</subject><subject>Heart attacks</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Implantation</subject><subject>Implants</subject><subject>Inhibitor drugs</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Middle Aged</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - surgery</subject><subject>Myocardial Infarction - therapy</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Percutaneous Coronary Intervention - adverse effects</subject><subject>Physical Sciences</subject><subject>Polymers</subject><subject>Proportional Hazards Models</subject><subject>Republic of Korea</subject><subject>Risk assessment</subject><subject>Scaffolds</subject><subject>Stents</subject><subject>Studies</subject><subject>Surgical implants</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Thrombosis - etiology</subject><subject>Tissue Scaffolds - adverse effects</subject><subject>Treatment Outcome</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkk2P0zAQhiMEYpeFf4AgEhLikuKPxHEuSKsVHyuttBc4WxNn3Lpy42I7K_rvcdvsqkWcbI2fed-Z8RTFW0oWlLf089pPYQS32PoRF4TxRrT8WXFJO84qwQh_fnK_KF7FuCak4VKIl8UFZ6JuCOsuiz_3I1Y7hFCiMVaD3pUwDmUEg2lXelPiAwbv7GaKFbop2XFZ9tYHjD700DssowZjvBtiaccyrXIA0wHLyaCnhOVm5zWEwYLLiIGgk_Xj6-KFARfxzXxeFb--ff1586O6u_9-e3N9V-mGNqmqcdB9B0gGxhkQjZKKHjRvBafZn_RykHXNB1I3UgDllANSIoUetGStbPlV8f6ou3U-qnloUbGaMUKkFF0mbo_E4GGttsFuIOyUB6sOAR-WCkKy2qFqZW9As46TbqhNttRN32rdNcZwPfRN1voyu039JpeOYwrgzkTPX0a7Ukv_oFpet5TyLPBpFgj-94QxqY2NGp2DEf10qJuTRtSSZvTDP-j_u5upJeQG8vx99tV7UXUtWEeo5GKv9fGEWiG4tIp-_99-jOdgfQR18DEGNE-9UaL2e_lYhNrvpZr3Mqe9O53LU9LjIvK_tBjhyA</recordid><startdate>20200709</startdate><enddate>20200709</enddate><creator>Kim, Yongcheol</creator><creator>Bae, SungA</creator><creator>Jeong, Myung Ho</creator><creator>Ahn, Youngkeun</creator><creator>Kim, Chong Jin</creator><creator>Cho, Myeong Chan</creator><creator>Baumbach, Andreas</creator><creator>Gogas, Bill D</creator><creator>King, 3rd, Spencer B</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2424-810X</orcidid><orcidid>https://orcid.org/0000-0003-1484-4645</orcidid><orcidid>https://orcid.org/0000-0002-0047-0227</orcidid></search><sort><creationdate>20200709</creationdate><title>One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction</title><author>Kim, Yongcheol ; Bae, SungA ; Jeong, Myung Ho ; Ahn, Youngkeun ; Kim, Chong Jin ; Cho, Myeong Chan ; Baumbach, Andreas ; Gogas, Bill D ; King, 3rd, Spencer B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-4edcb9ae0d232a0ce816bac37631bab0b8d8443d04586a1313ae1086cdc827873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Absorbable Implants - adverse effects</topic><topic>Acute Disease - therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Biocompatibility</topic><topic>Biology and Life Sciences</topic><topic>Biomedical materials</topic><topic>Cardiology</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Care and treatment</topic><topic>Clinical outcomes</topic><topic>Confidence intervals</topic><topic>Consent</topic><topic>Drug-Eluting Stents - adverse effects</topic><topic>Endpoint Determination</topic><topic>Engineering and Technology</topic><topic>Everolimus - therapeutic use</topic><topic>Female</topic><topic>Glycoproteins</topic><topic>Heart attack</topic><topic>Heart attacks</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Implantation</topic><topic>Implants</topic><topic>Inhibitor drugs</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Middle Aged</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - surgery</topic><topic>Myocardial Infarction - therapy</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Percutaneous Coronary Intervention - adverse effects</topic><topic>Physical Sciences</topic><topic>Polymers</topic><topic>Proportional Hazards Models</topic><topic>Republic of Korea</topic><topic>Risk assessment</topic><topic>Scaffolds</topic><topic>Stents</topic><topic>Studies</topic><topic>Surgical implants</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Thrombosis - etiology</topic><topic>Tissue Scaffolds - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Yongcheol</creatorcontrib><creatorcontrib>Bae, SungA</creatorcontrib><creatorcontrib>Jeong, Myung Ho</creatorcontrib><creatorcontrib>Ahn, Youngkeun</creatorcontrib><creatorcontrib>Kim, Chong Jin</creatorcontrib><creatorcontrib>Cho, Myeong Chan</creatorcontrib><creatorcontrib>Baumbach, Andreas</creatorcontrib><creatorcontrib>Gogas, Bill D</creatorcontrib><creatorcontrib>King, 3rd, Spencer B</creatorcontrib><creatorcontrib>Other Korea Acute Myocardial Infarction Registry Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Yongcheol</au><au>Bae, SungA</au><au>Jeong, Myung Ho</au><au>Ahn, Youngkeun</au><au>Kim, Chong Jin</au><au>Cho, Myeong Chan</au><au>Baumbach, Andreas</au><au>Gogas, Bill D</au><au>King, 3rd, Spencer B</au><aucorp>Other Korea Acute Myocardial Infarction Registry Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-07-09</date><risdate>2020</risdate><volume>15</volume><issue>7</issue><spage>e0235673</spage><pages>e0235673-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>This study sought to compare clinical outcomes between bioresorbable scaffolds (BRS) and durable polymer everolimus-eluting metallic stents (DP-EES) in patients with acute myocardial infarction (AMI) undergoing successful percutaneous coronary intervention (PCI).
From March 2016 to October 2017, 952 patients with AMI without cardiogenic shock undergoing successful PCI with BRS (n = 136) or DP-EES (n = 816) were enrolled from a multicenter, observational Korea Acute Myocardial Infarction Registry.
In the crude population, there was no significant difference in the 1-year rate of device-oriented composite endpoint (DOCE) and device thrombosis between the BRS and DP-EES groups (2.2% vs. 4.8%, hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.13-1.41, p = 0.163; 0.7% vs. 0.5%, HR 1.49, 95% CI 0.16-13.4, p = 0.719, respectively). BRS implantation was opted in younger patients (53.7 vs. 62.6 years, p < 0.001) with low-risk profiles, and intravascular image-guided PCI was more preferred in the BRS group (60.3% vs. 27.2%, p < 0.001).
At 1-year follow-up, no differences in the rate of DOCE and device thrombosis were observed between patients with AMI treated with BRS and those treated with DP-EES. Our data suggest that imaging-guided BRS implantation in young patients with low risk profiles could be a reasonable strategy in the setting of AMI.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>32645029</pmid><doi>10.1371/journal.pone.0235673</doi><orcidid>https://orcid.org/0000-0003-2424-810X</orcidid><orcidid>https://orcid.org/0000-0003-1484-4645</orcidid><orcidid>https://orcid.org/0000-0002-0047-0227</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-07, Vol.15 (7), p.e0235673 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2422008869 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Absorbable Implants - adverse effects Acute Disease - therapy Adult Aged Biocompatibility Biology and Life Sciences Biomedical materials Cardiology Cardiovascular Agents - therapeutic use Care and treatment Clinical outcomes Confidence intervals Consent Drug-Eluting Stents - adverse effects Endpoint Determination Engineering and Technology Everolimus - therapeutic use Female Glycoproteins Heart attack Heart attacks Hospitals Humans Hypertension Implantation Implants Inhibitor drugs Male Medicine Medicine and Health Sciences Middle Aged Myocardial infarction Myocardial Infarction - surgery Myocardial Infarction - therapy Patient outcomes Patients Percutaneous Coronary Intervention - adverse effects Physical Sciences Polymers Proportional Hazards Models Republic of Korea Risk assessment Scaffolds Stents Studies Surgical implants Thromboembolism Thrombosis Thrombosis - etiology Tissue Scaffolds - adverse effects Treatment Outcome |
| title | One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A12%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=One-year%20efficacy%20and%20safety%20of%20everolimus-eluting%20bioresorbable%20scaffolds%20in%20the%20setting%20of%20acute%20myocardial%20infarction&rft.jtitle=PloS%20one&rft.au=Kim,%20Yongcheol&rft.aucorp=Other%20Korea%20Acute%20Myocardial%20Infarction%20Registry%20Investigators&rft.date=2020-07-09&rft.volume=15&rft.issue=7&rft.spage=e0235673&rft.pages=e0235673-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0235673&rft_dat=%3Cgale_plos_%3EA629018361%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2422008869&rft_id=info:pmid/32645029&rft_galeid=A629018361&rft_doaj_id=oai_doaj_org_article_78bfac29309d4f458c5b7cc95ff3cdb5&rfr_iscdi=true |